David H. Vesole

Also affiliated with Georgetown University, Georgetown University Medical Center, MedStar Georgetown University Hospital, Edwards Comprehensive Cancer Center, Hackensack Meridian Health

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).”.

Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8506

N/A

0DataRank · unranked

102 citations

Marcelo C. Pasquini, Edward A. Stadtmauer, Raphael Fraser, Mingwei Fei, Steven M. Devine +14 more

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7003

N/A

0DataRank · unranked

2 citations

Qaiser Bashir, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +11 more

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

Leukemia(2021)10.1038/s41375-021-01233-1

N/A

0DataRank · unranked

1 citations

Sagar S. Patel, Saulius Girnius, Lohith Bachegowda, Raphael Fraser, Omar Dávila +42 more

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.007

N/A

0DataRank · unranked

9 citations

T Nishihori, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +15 more

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Blood Advances(2023)10.1182/bloodadvances.2022009138

N/A

0DataRank · unranked

36 citations

Mithun Vinod Shah, Anita D’Souza, Noel Estrada‐Merly, Lohith Gowda, Gemlyn George +37 more